CheckMate 274 Confirms Benefit of Nivolumab for Bladder Cancer

Bladder Cancer Advocacy Network Announces National Presenting Sponsorships by Ferring Pharmaceuticals and the Astellas/Pfizer Alliance for the 2025 Walks to End Bladder Cancer

Partnerships to help create more todays and better tomorrows for bladder cancer patients and families

JCI Asparagine drives immune evasion in bladder cancer via RIG-I stability and type I IFN signaling

Tumor cells often employ many ways to restrain type I IFN signaling to evade immune surveillance. However, whether cellular amino acid metabolism regulates this process remains unclear, and its effects on antitumor immunity are relatively unexplored. Here, we found that asparagine inhibited IFN-I signaling and promoted immune escape in bladder cancer. Depletion of asparagine synthetase (ASNS) strongly limited in vivo tumor growth in a CD8+ T cel…

CheckMate 274 Confirms Benefit of Nivolumab for Bladder Cancer

During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in patients with high PD-L1.